Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Cidara Therapeutics (CDTX) Return on Equity: 2018-2025

Historic Return on Equity for Cidara Therapeutics (CDTX) over the last 8 years, with Sep 2025 value amounting to -0.29%.

  • Cidara Therapeutics' Return on Equity fell 33.00% to -0.29% in Q3 2025 from the same period last year, while for Sep 2025 it was -0.29%, marking a year-over-year decrease of 33.00%. This contributed to the annual value of 0.01% for FY2024, which is 20.00% up from last year.
  • According to the latest figures from Q3 2025, Cidara Therapeutics' Return on Equity is -0.29%, which was down 85.81% from -0.15% recorded in Q2 2025.
  • In the past 5 years, Cidara Therapeutics' Return on Equity registered a high of 6.46% during Q2 2022, and its lowest value of -44.28% during Q1 2023.
  • Moreover, its 3-year median value for Return on Equity was -0.14% (2025), whereas its average is -3.84%.
  • Per our database at Business Quant, Cidara Therapeutics' Return on Equity plummeted by 3,951bps in 2023 and then soared by 4,371bps in 2024.
  • Over the past 5 years, Cidara Therapeutics' Return on Equity (Quarterly) stood at -4.16% in 2021, then skyrocketed by 851bps to 4.35% in 2022, then plummeted by 614bps to -1.79% in 2023, then spiked by 179bps to 0.00% in 2024, then slumped by 33bps to -0.29% in 2025.
  • Its last three reported values are -0.29% in Q3 2025, -0.15% for Q2 2025, and -0.14% during Q1 2025.